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Background To test the hypothesis that troponin I and echocardiography have an
incremental prognostic value in patients with pulmonary embolism (PE).
Methods and results In 91 patients with acute PE, echocardiography was performed
within 4 h of admission. Troponin I levels were obtained on admission and 12 h
thereafter. The 0.06 µg/l troponin I cut-off level was identified as the most useful,
high-sensitivity cut-off level for the prediction of adverse outcome by receiver
operating characteristic analysis with a sensitivity and specificity of 86%, respectively.
Twenty-eight (31%) patients had elevated troponin I levels (4.9±3.8 µg/l). Twenty-one
(23%) patients had adverse clinical outcomes including in-hospital death in five,
cardiopulmonary resuscitation in four, mechanical ventilation in six, pressors in 14,
thrombolysis in 14, catheter fragmentation in three, and surgical embolectomy in
three. The area under the receiver operating characteristic curve from multivariate
regression models for predicting adverse outcome without troponin I and echo-
cardiography (0.765), with troponin I (0.890) or echocardiography alone (0.858),
and the combination of both tests (0.900) was incremental. Three-month survival
rate was highest in patients with both a normal troponin I level and a normal echo-
cardiogram (98%). Positive predictive value for adverse clinical outcomes of the
combination of echocardiography and troponin I was higher (75% (95%CI 55–88%))
compared with each test alone (echocardiography: 41%, 95% CI 28–56%; troponin I:
64%, 95% CI 46–79%).
Conclusions While troponin I measurements added most of the prognostic information
for identifying high-risk patients, a normal echocardiogram combined with a negative
troponin I level was most useful to identify patients at lowest risk for early death.
© 2003 Published by Elsevier Ltd on behalf of The European Society of Cardiology.
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Introduction
Right ventricular dysfunction was the single most import-
ant predictor of in-hospital death in the international
registry of 2454 patients with pulmonary embolism (PE).1
Therefore, echocardiography has emerged as important
diagnostic tool for assessing the degree of right ventricu-
lar dysfunction in patients with acute PE.
Recently, cardiac troponins I and T have also been
shown to be associated with early mortality and a com-
plicated hospital course in patients with PE.2–4 However,
the prognostic role of cardiac troponins in PE patients
who undergo risk stratification, including assessment of
right ventricular function by echocardiography, is less
clear. We aimed to test the hypothesis that troponin I and
echocardiography have an incremental prognostic value
in PE patients.
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Methods
Patients
In consecutive symptomatic PE patients from the Emergency
Department of the University Hospital of Bern, the diagnosis was
confirmed by spiral computed tomography (CT) in 86, high
probability ventilation perfusion scan in three, and pulmonary
angiography in two patients during a study period of 18 months.
Troponin I levels were taken in all 91 patients on admission and
12 h thereafter using a microparticle enzyme immunoassay
(Abbott, USA). The study protocol was approved by the local
ethics committee, and written informed consent was obtained
from all patients.
Spiral computed tomography, ventilation
perfusion scan, and pulmonary angiography
Pulmonary embolism was diagnosed by spiral CT when there was
at least one intravascular filling defect in a pulmonary artery
using a standard protocol.5 Lung scans were interpreted accord-
ing to the PIOPED criteria.6 PE was diagnosed by pulmonary
angiography when there was at least one intravascular filling
defect in a pulmonary artery using a standard protocol.7
Transthoracic echocardiography
Echocardiography was performed in all patients with PE within
4 h after admission using an Acuson Sequoia™ C256 system
(Mountain View, California, USA) with a 3.5 MHz probe and
three-lead electrocardiographic monitoring. Echocardiographic
off-line analysis was interpreted by a cardiologist who was
unaware of clinical data and troponin I levels. Right ventricular
end-diastolic diameter was measured either from the apical or
subcostal four-chamber view in 85 (93%) patients. The maximal
distance between the endocardium of the right ventricular free
wall and the interventricular septum, perpendicular to the long
axis of the ventricle, was measured at the beginning of the
QRS-complex. Tricuspid pressure gradient as a surrogate of
systolic pulmonary artery pressure was available in 70 (77%)
patients. Right ventricular systolic function was assessed in
all patients using a 4-point scale, i.e., normal/near normal
right ventricular systolic function, moderate to severe right
ventricular systolic dysfunction.8,9
Treatment strategy
Reperfusion therapy, including thrombolysis, catheter fragmen-
tation, or surgical embolectomy was performed in patients with
PE and a shock index ≥1 (heart rate divided by systolic blood
pressure).10 Thrombolysis was also considered in the absence of
contraindications according to the Task Force of the European
Society of Cardiology (ESC)11 in patients with a shock index
<1 but moderate to severe right ventricular dysfunction. All
patients with normal/near normal right ventricular function on
the echocardiogram were treated with heparin alone.
Statistical analysis
Adverse clinical outcome was defined as in-hospital death or the
need for cardiopulmonary resuscitation, mechanical ventilation,
pressors, thrombolysis, catheter fragmentation, or surgical
embolectomy according to the MAPPET-3 criteria.12
Table 1 and Table 2 data are presented as numbers of
patients with proportions in parentheses or mean±SD values.
Receiver operating charcteristic (ROC) analysis was performed
to identify the most useful troponin I cut-off level for the
prediction of adverse outcome. Nominal data comparison be-
tween the troponin groups (cut-off 0.06 µg/l) was performed
using a 2 test. Continuous echocardiographic and haemody-
namic data between the troponin groups were compared with
the Student t-test.
Multivariate logistic regression was performed on univari-
ately significant continuous and categorical variables (P<0.05)
from Table 1 for predicting adverse clinical outcomes. To inves-
tigate whether troponin I and echocardiography have incremen-
tal prognostic value in addition to clinical parameters, we also
calculated resulting areas under the ROC curve for multivariate
models without troponin and echocardiography, with troponin I
and echocardiography alone, and with the combination of both
tests. All models were adjusted for univariately significant
(P<0.05) predictors of adverse outcome from Table 1.
Kaplan–Meier analyses were performed to investigate cumu-
lative 3-month survival rates according to troponin I levels and
the presence or absence of right ventricular dysfunction. Data
were considered significant at P<0.05.
Results
None of the 91 patients had evidence for acute coronary
syndromes, including right ventricular infarction, based
on electrocardiograms, echocardiograms, and creatine
kinase-MB levels. Twenty eight (31%) patients had el-
evated troponin I levels (4.9±3.8, range 0.7–14.6 µg/l).
Syncope and dyspnea were more prevalent in patients
with a troponin I leak than in patients with a normal
troponin I level (Table 1). The history and risk factors for
coronary artery disease were similar in patients with and
without troponin I elevation. Haemodynamic changes
were more severe and moderate to severe right ventricu-
lar dysfunction more frequent in patients with than
without elevated troponin I levels. Right ventricular dila-
tation was pronounced, and tricuspid pressure gradients
were also higher in patients with elevated troponin I
levels. More patients had paracentral or central pulmon-
ary artery filling defects as assessed by spiral CT in the
elevated troponin I group.
In-hospital mortality was 5%, and all five deaths were
attributed to right ventricular failure. Four of these
patients had elevated troponin I levels. Twenty one (23%)
patients had adverse clinical outcomes including cardio-
pulmonary resuscitation in four, mechanical ventilation
in six, pressors in 14, thrombolysis in 14, catheter frag-
mentation in three, and surgical embolectomy in three
patients. Detailed combinations of adverse clinical out-
comes are shown in Table 2 The 0.06 µg/l troponin I
cut-off level was identified as the most useful, high-
sensitivity cut-off level for the prediction of adverse
outcome by receiver operating characteristic analysis
with a sensitivity and specificity of 86%, respectively.
Normal troponin I levels were associated with a higher
3-month survival rate than in patients with troponin I
levels ≥0.06 µg/l (Fig. 1). Three-month survival rate was
highest in patients with both a normal troponin I level and
a normal echocardiogram (Fig. 2).
Specificity and positive predictive value for adverse
clinical events were higher using the combination of
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troponin I and echocardiography compared with that of
each test individually (Table 3). Sensitivity and negative
predictive value for adverse outcomes were similar for
troponin I, echocardiography, and the combination of
both tests.
In a multivariate regression model, troponin I eleva-
tion was an independent predictor of adverse outcome
when adjusted for right ventricular function on the
echocardiogram and other univariate predictors of ad-
verse outcome (Table 4). The area under the ROC curve
Table 1 Baseline characteristics of 91 patients with pulmonary embolism
Total Troponin I ≥0.6 µg/l Troponin I <0.6 µg/l
n 91 28 63
Age, years 61±17 62±17 61±18
Men, n (%) 41 15 (54) 36 (57)
Symptoms, n (%)
Dyspnoea 40 25 (89)† 35 (56)
Chest pain 38 13 (46) 25 (40)
Syncope 12 9 (32)† 3 (5)
Comorbidities, n (%)
Chronic lung disease 11 3 (11) 8 (13)
Valvular heart disease 4 1 (4) 3 (5)
Percutaneous coronary intervention 4 1 (4) 3 (5)
Coronary artery bypass graft 2 1 (4) 1 (2)
Previous myocardial infarction 8 3 (11) 5 (8)
Angina pectoris 6 2 (7) 4 (6)
Smoking 19 7 (25) 12 (19)
Hypercholesterolaemia 22 8 (29) 14 (22)
Systemic hypertension 21 7 (25) 14 (22)
Diabetes mellitus 2 0 2 (3)
Family history for coronary artery disease 8 3 (11) 5 (8)
Haemodynamic and echocardiographic data
Systolic blood pressure, mmHg 120±17 102±15* 127±17
Heart rate, beats per minute 85±15 97±15* 81±16
Shock index, bpm/mmHg 0.71±0.17 0.98±0.27* 0.65±0.18
Right ventricular end-diastolic diameter, mm 41±6 48±6* 40±6
Tricuspid systolic gradient, mmHg 45±18 57±16† 43±18
Moderate/severe right ventricular dysfunction, n (%) 46 24 (86)* 22 (35)
Paracentral PE 39 22 (79)* 17 (27)
Shock index: heart rate divided by systolic arterial blood pressure; Paracentral PE: ≥1 subtotal filling defect in ≥1 lobar or main pulmonary artery by
spiral CT
*P<0.001.
†P<0.01.
Table 2 Combinations of adverse clinical outcomes in 21 patients according to the presence or absence of a troponin I leak
Adverse clinical outcomes Troponin ≥0.06 µg/l Troponin <0.06 µg/l
Thrombolysis* 2 1
Pressors 1 1
Pressors+ventilation+death 2 —
Pressors+thrombolysis 3 —
Pressors+thrombolysis+death 1 1
Pressors+catheter fragmentation 1 —
Pressors+catheter fragmentation+thrombolysis 2 —
Surgical embolectomy 1 —
Pressors+ventilation+embolectomy 1 —
CPR+pressors+ventilation+embolectomy+death 1 —
CPR+thrombolysis 1 —
CPR+ventilation+thrombolysis 1 —
CPR+pressors+ventilation+thrombolysis+death 1 —
*Patients with right ventricular dysfunction and a shock index <1 (heart rate divided by systolic arterial blood pressure). CPR: cardiopulmonary
resuscitation.
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obtained from multivariate regression models were:
0.765 for the model without troponin I and echocardiog-
raphy, 0.890 for troponin I alone, 0.858 for echocardiog-
raphy alone, and 0.900 for the combination of both tests.
Discussion
In the present study of 91 patients with acute PE, the
combination of troponin I and echocardiography had ad-
ditional prognostic information compared with troponin I
or echocardiography alone. The area under the ROC
curve from multivariate regression models for predicting
adverse outcome without troponin I and echocardiogra-
phy (0.765), with troponin I (0.890) or echocardiography
alone (0.858), and the combination of both tests (0.900)
was incremental. The biggest addition of prognostic in-
formation was obtained with troponin I measurements.
Although the area under the curve did no increase much
Fig. 1 Cumulative 90-day survival rate in 91 patients with pulmonary embolism according to troponin I levels (cTnI cut-off 0.06 µg/l).
Fig. 2 Cumulative 90-day survival rate in 91 patients with pulmonary embolism based on troponin I levels (cTnI cut-off 0.06 µg/l) and right ventricular
function on the echocardiogram.
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with addition of echocardiography to troponin I results,
it appears to be useful in identifying low-risk patients
because patients with a normal troponin I level and a
normal echocardiogram had the lowest mortality rate
(Fig. 2). The positive predictive value and specificity for
predicting adverse outcomes were higher with the com-
bination of troponin I and echocardiography compared
with each test alone (Table 3).
The prevalence of increased cardiac troponin I levels
was 31%. A similar prevalence was also found in three
recent studies in patients with PE using different tro-
ponin assays: 18 (32%) of 56 patients using a qualitative
troponin T assay,4 14 (39%) of 36 patients using a quali-
tative troponin I assay,3 and 43 (41%) of 106 patients
using a quantitative troponin I assay.2 In the cited and
in the present study, cardiac troponin was a predictor
of right ventricular dysfunction and adverse clinical
outcomes in patients with PE.
In the present study, four of the 28 patients with a
troponin I leak had preserved right ventricular function
on echocardiography. Thus, right ventricular dysfunction
should be confirmed in all troponin-positive PE patients
with risk factors for coronary artery disease. Echocardi-
ography is an important diagnostic and prognostic tool in
patients with PE, and an increasing number of hospitals
use echocardiography for risk stratification of their PE
patients.
The present study is limited by the selection of ad-
verse clinical outcomes used to define the combined
end-point, including the need for thrombolysis and em-
bolectomy. Ten of 13 patients who received thrombolysis
fulfilled the criteria for clinically massive PE with shock
or systemic hypotension according to the ESC guide-
lines.11 The remaining three patients with thrombolysis
had submassive PE, defined as a preserved systolic ar-
terial pressure and evidence of right ventricular dysfunc-
tion. According to the ESC guidelines,11 thrombolysis may
also be considered in patients with submassive PE when
no contraindications to thrombolysis are present. In con-
trast to MAPPET-3,12 the decision to initiate reperfusion
therapy was based on the initial clinical presentation of
the patient, particularly on shock index and echocardio-
graphic findings, and not on secondary clinical deteriora-
tion. Thus, this study allows no conclusion about the
prognostic value of echocardiography and troponin I in
the prediction of secondary clinical deterioration in
patients with elevated troponin I levels and right ven-
tricular dysfunction who receive standard treatment with
heparin alone.
Conclusions
In patients with acute PE, troponin I and echocardiogra-
phy have an incremental prognostic value for adverse
clinical outcomes including death, the need for cardio-
pulmonary resuscitation, mechanical ventilation, pres-
sors, thrombolysis, catheter fragmentation, and surgical
embolectomy. While troponin I measurements added
most of the prognostic information for identifying high-
risk patients, a normal echocardiogram combined with a
negative troponin I level was most useful to identify
patients at lowest risk for early death.
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